Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 11. RPL22L1 can activate MDM2/p53. (A) Western blotting showed the effect of PRL22L1 knockdown on the expression of MDM2/p53. (B) The CCK-8 experiment demonstrated the impact of RPL22L1 knockdown in combination with pifithrin-α on the proliferative capacity of A549 cells. (C) The wound healing assay revealed the influence of PRL22L1 knockdown in conjunction with pifithrin-α on the migratory ability of A549 cells. (D) The cloning experiments exhibited the effect of PRL22L1 knockdown in combination with pifithrin-α on the proliferation capability of A549 cells. (E) The transwell experiment demonstrated the impact of PRL22L1 knockdown in conjunction with pifithrin-α on the invasive potential of A549 cells. (F) The flow cytometry analysis revealed the influence of PRL22L1 knockdown in combination with pifithrin-α on the apoptotic ability of A549 cells. *, p < 0.05, **, p < 0.01; ***, p < 0.001.